HUE060152T2 - 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk - Google Patents

4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk

Info

Publication number
HUE060152T2
HUE060152T2 HUE16869945A HUE16869945A HUE060152T2 HU E060152 T2 HUE060152 T2 HU E060152T2 HU E16869945 A HUE16869945 A HU E16869945A HU E16869945 A HUE16869945 A HU E16869945A HU E060152 T2 HUE060152 T2 HU E060152T2
Authority
HU
Hungary
Prior art keywords
indol
pyrimidin
pyridin
preparation
protein kinase
Prior art date
Application number
HUE16869945A
Other languages
English (en)
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Gan & Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE060152(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceuticals filed Critical Gan & Lee Pharmaceuticals
Publication of HUE060152T2 publication Critical patent/HUE060152T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
HUE16869945A 2015-11-30 2016-11-28 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk HUE060152T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
HUE060152T2 true HUE060152T2 (hu) 2023-02-28

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16869945A HUE060152T2 (hu) 2015-11-30 2016-11-28 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk

Country Status (21)

Country Link
US (2) US11091476B2 (hu)
EP (1) EP3385262B1 (hu)
JP (2) JP6921101B2 (hu)
KR (1) KR20180083421A (hu)
CN (3) CN106810536A (hu)
AU (1) AU2016365366B2 (hu)
BR (1) BR112018010879A2 (hu)
CA (1) CA3002884A1 (hu)
CO (1) CO2018005854A2 (hu)
DK (1) DK3385262T3 (hu)
ES (1) ES2928169T3 (hu)
HU (1) HUE060152T2 (hu)
IL (1) IL259711B (hu)
MA (1) MA42341B2 (hu)
MX (1) MX2018006370A (hu)
PH (1) PH12018550049A1 (hu)
PT (1) PT3385262T (hu)
RU (1) RU2749437C2 (hu)
UA (1) UA124001C2 (hu)
WO (1) WO2017092635A1 (hu)
ZA (1) ZA201803531B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
JP7100125B2 (ja) 2017-10-27 2022-07-12 フレゼニウス・カビ・オンコロジー・リミテッド リボシクリブおよびその塩の改善された調製のためのプロセス
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2019170055A1 (zh) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途
EA202191938A1 (ru) * 2019-01-29 2021-10-13 Бета Фарма, Инк. Производные 2h-индазола в качестве терапевтических средств при видах рака головного мозга и метастазах в головной мозг
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
US20220315532A1 (en) 2019-06-21 2022-10-06 Gan & Lee Pharmaceuticals Co., Ltd. Methods for preparing cdk4/6 inhibitor and salt and intermediate thereof
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
EP4263525A1 (en) * 2020-12-18 2023-10-25 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
CN117222636A (zh) * 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
CN117337284A (zh) * 2021-05-17 2024-01-02 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023040914A1 (zh) * 2021-09-14 2023-03-23 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023116862A1 (zh) * 2021-12-24 2023-06-29 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
CN117658987A (zh) * 2022-09-08 2024-03-08 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
BR0108085A (pt) 2000-02-07 2003-03-18 Abbott Gmbh & Co Kg Derivados de 2-benzotiazolil uréia e seu uso como inibidores da cinase protéica
CN101001857B (zh) * 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
US20070117818A1 (en) * 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
WO2007089768A2 (en) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
PT2265607T (pt) * 2008-02-15 2017-03-08 Rigel Pharmaceuticals Inc Compostos de pirimidina-2-amina e sua utilização como inibidores de jak cinases
KR101368079B1 (ko) 2008-05-16 2014-03-14 에프. 호프만-라 로슈 아게 Ｊｎｋ 의 억제제
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (en) * 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN111212842B (zh) 2017-09-05 2022-10-25 布莱克索恩治疗公司 血管加压素受体拮抗剂以及与其相关的产品和方法
CN117222636A (zh) 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Also Published As

Publication number Publication date
CN113956238A (zh) 2022-01-21
CN108290864B (zh) 2022-05-10
EP3385262A1 (en) 2018-10-10
RU2018122864A (ru) 2020-01-13
AU2016365366B2 (en) 2021-03-04
PT3385262T (pt) 2022-10-18
IL259711B (en) 2022-08-01
ZA201803531B (en) 2021-10-27
WO2017092635A1 (zh) 2017-06-08
MA42341B2 (fr) 2021-05-31
BR112018010879A2 (pt) 2018-11-21
US20200165239A1 (en) 2020-05-28
RU2749437C2 (ru) 2021-06-10
CN113956238B (zh) 2023-07-14
CN108290864A (zh) 2018-07-17
PH12018550049A1 (en) 2018-10-29
EP3385262A4 (en) 2019-06-19
US11091476B2 (en) 2021-08-17
JP2021138737A (ja) 2021-09-16
MA42341A1 (fr) 2018-06-29
DK3385262T3 (da) 2022-10-10
CN106810536A (zh) 2017-06-09
US11787801B2 (en) 2023-10-17
ES2928169T3 (es) 2022-11-15
EP3385262B1 (en) 2022-07-13
US20210371418A1 (en) 2021-12-02
JP6921101B2 (ja) 2021-08-18
UA124001C2 (uk) 2021-07-07
KR20180083421A (ko) 2018-07-20
AU2016365366A1 (en) 2018-05-17
JP2019500413A (ja) 2019-01-10
CO2018005854A2 (es) 2018-06-20
IL259711A (en) 2018-07-31
RU2018122864A3 (hu) 2020-03-17
MX2018006370A (es) 2018-09-24
CA3002884A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
HUE060152T2 (hu) 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk
EP3647311C0 (en) RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD AND USE THEREOF
EP3310339A4 (en) OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHOD OF USE THEREOF AND METHOD OF PRODUCTION THEREOF
ZA201700652B (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
ZA201908609B (en) Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
IL252477B (en) History of 2-[(ethenyl-carbonyl-amino)anilino]-pyrimidine, process for their preparation and pharmaceutical preparations containing them
HK1253537A1 (zh) 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法
EP3369734A4 (en) KINASEINHIBITOR AND METHOD OF PREPARATION AND PHARMACEUTICAL USE THEREOF
HUE059672T2 (hu) Kinolinvegyületek, eljárás azok elõállítására, és urát transzporter inhibitor gyógyzserként történõ alkalmazásuk
IL250447A0 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors and methods for their preparation
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
EP3347462A4 (en) METHOD, COMPOSITIONS AND USE OF NOVEL FYN KINASEINHIBITORS
EP3459952A4 (en) PYRIMIDINE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF IN MEDICINE
ZA201808014B (en) Adenine derivatives as protein kinase inhibitors
IL304547A (en) 3-substituted benzamide derivatives as kinase inhibitors
IL267829B (en) History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use
EP3176160A4 (en) Pyridine-substituted 2-aminopyridine protein kinase inhibitors
HK1248601A1 (zh) 作為激酶抑制劑的嘧啶衍生物及其治療應用
EP3219311A4 (en) Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition